DEA Special Agent David Howell, who filed a whistleblower complaint, poses for a portrait outside the U.S. district courthouse in Albuquerque, N.M., on June 12. (AP Photo/Susan Montoya Bryan)

The federal Drug Enforcement Administration on Thursday asked the U.S. Justice Department’s internal watchdog to investigate a whistleblower’s claims that DEA agents permitted hundreds of thousands of fentanyl pills to hit the streets of New Mexico.

The request came days after an Associated Press investigation found agents repeatedly monitored — but did not seize — major shipments of the synthetic opioid in a bid to build bigger criminal cases between 2023 and 2025.

In a letter sent Thursday to the U.S. Justice Department’s Inspector General, DEA administrator Terry Cole wrote that an internal probe was necessary because “the allegations have generated significant public attention and have raised questions regarding DEA’s operational decisions, supervisory oversight, and response to concerns.”

Cole wrote in a public statement that his request “should not be interpreted as reflecting any lack of confidence in the professionalism or integrity of DEA personnel or in the investigative decisions made during this matter.”

“If improvements are identified, DEA will implement them,” he added. “Strong institutions are sustained — not diminished — by objective oversight and a willingness to continuously assess and improve.”

Current and former DEA agents told the AP the investigative strategy — known as letting the counterfeit painkillers “walk” — amounted to a gamble with public safety in a state ravaged by the fentanyl epidemic and may have violated Justice Department rules intended to safeguard communities from a drug the White House last year designated as a ” weapon of mass destruction.”

The AP investigation cited three current and former agents and government records, including an internal report of a 2023 delivery of 74,000 pills the DEA watched happen at a mobile home park in Albuquerque. One of those agents, David Howell, first raised serious concerns about this strategy in a 2023 whistleblower complaint. He continued to raise his objections internally and spoke at length with the AP about what he described as a strategy that “poisoned our community to make cases.”

In an earlier statement to AP, a DEA spokesperson said “public descriptions suggesting that DEA knowingly permitted fentanyl to reach communities are false and fundamentally mischaracterize the facts.”